Sign in

You're signed outSign in or to get full access.

FB

Fortress Biotech, Inc. (FBIO)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 delivered modest topline growth and a narrower loss: consolidated net product revenue was $13.139M and net loss per common share was $($0.48), with total operating expenses down 28% year over year on sharply lower R&D spend . Versus Q4 2024, revenue was lower and operating expenses were slightly higher, while cash rose materially on subsidiary-level inflows *.
  • Fortress beat Wall Street consensus on both revenue and EPS: revenue of $13.139M vs $11.621M consensus and EPS of $(0.48) vs $(0.495) (two estimates). The beats were modest but notable given thin coverage and the early Emrosi launch contribution at quarter-end *.
  • Strategic catalysts remain central: Sun Pharma’s pending acquisition of Checkpoint (expected ~$28M at closing plus 2.5% UNLOXCYT royalty and potential CVR) and the CUTX-101 priority review (PDUFA Sept 30, 2025) position Fortress for monetization and optionality .
  • Management highlighted Emrosi’s commercial launch and initial prescriptions, as well as an AI collaboration with Partex to accelerate BD pipeline evaluation—supportive of medium-term revenue and bolt-on asset sourcing .
  • Near-term stock reaction catalysts: Checkpoint deal closing and any Emrosi uptake updates; mid-term, CUTX-101 approval decision and potential PRV monetization .

Note: Values marked with * are retrieved from S&P Global.

What Went Well and What Went Wrong

What Went Well

  • Emrosi commercial launch initiated with initial prescriptions filled at the end of March; management believes Emrosi can be a “new treatment paradigm” for rosacea . “Commercial launch of Emrosi is also underway with initial prescriptions filled at the end of March” — Lindsay A. Rosenwald, M.D. .
  • Revenue and EPS beat consensus modestly (two-estimate sample), indicating early momentum and cost discipline versus prior year: $13.139M vs $11.621M revenue consensus; EPS $(0.48) vs $(0.495) *.
  • Q1 operating expenses down sharply YoY due to a significant reduction in R&D ($3.9M vs $24.8M YoY), narrowing loss to $(0.48) per share versus $(1.04) in Q1 2024 .

What Went Wrong

  • Sequential softening in revenue versus Q4 2024, while SG&A elevated to $25.7M (vs $17.9M in Q1 2024), reflecting commercialization and corporate costs—pressuring operating loss *.
  • Limited disclosure on quantitative FY guidance; investor visibility on Emrosi ramp, UNLOXCYT royalty timing, and opex trajectory remains constrained .
  • Thin Street coverage (two estimates) can amplify volatility and reduces benchmark comparability; estimate dispersion and revision tracking remain limited [GetEstimates]*.

Financial Results

Consolidated Performance vs Prior Quarters and Year

MetricQ3 2024Q4 2024Q1 2025Q1 2024
Revenue ($USD Millions)$14.629 $14.120*$13.139 $13.030
Net Income - (IS) ($USD Millions)$(12.867) $(6.765)*$(10.584) $(15.417)
Diluted EPS - Continuing Operations ($USD)$(0.76) $(0.371)*$(0.48) $(1.04)
Total Operating Expenses ($USD Millions)$36.724 $34.220*$35.456 $49.596

Note: Values marked with * are retrieved from S&P Global.

Cash and Liquidity

MetricQ3 2024Q4 2024Q1 2025
Cash and Cash Equivalents ($USD Millions)$58.853 $57.263 $91.339
Cash Breakdown ($USD Millions)Fortress+Private: $25.6; Avenue: $2.6; Checkpoint: $4.7; Mustang: $3.5; Journey: $22.5 Fortress+Private: $20.9; Avenue: $2.6; Checkpoint: $6.6; Mustang: $6.8; Journey: $20.3 Fortress+Private: $19.5; Avenue: $3.5; Checkpoint: $33.0; Mustang: $14.2; Journey: $21.1

Operating Expense Detail (KPIs)

KPI ($USD Millions)Q3 2024Q4 2024Q1 2025Q1 2024
R&D Expense$9.446 $—$3.938 $24.839
SG&A Expense$21.993 $—$25.663 $17.941
Cost of Goods (excl. amort.)$5.285 $—$4.790 $6.002
Amortization of Intangibles$— $—$1.065 $0.814

Note: Q4 2024 line-item detail not provided in documents; refer to consolidated totals above and FY press release for context .

Segment/Source Notes

  • Revenue is generated from Journey Medical’s marketed dermatology products; Q1 2025 Journey net product revenue was $13.1M vs $13.0M in Q1 2024 .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
CUTX-101 PDUFA date (Priority Review)Q3 2025Not previously set in Q3’24Sept 30, 2025 (Priority Review) Established regulatory timeline
Emrosi Launch Timing1H 2025“Expected late Q1/early Q2 2025” Launch underway; first prescriptions filled end of March Executed per plan
Checkpoint Acquisition by Sun PharmaQ2 2025“Expected completion in Q2 2025” Special meeting May 28, 2025; close expected shortly after, subject to approvals Maintained timeline
Financial Guidance (Revenue/EPS/OpEx)FY 2025None disclosedNone disclosedN/A

Earnings Call Themes & Trends

Note: No Q1 2025 earnings call transcript located in our document set for FBIO over May–June 2025; the company appears to have provided results via press release/8-K .

TopicPrevious Mentions (Q3 2024)Previous Mentions (FY 2024, Mar 31)Current Period (Q1 2025)Trend
Emrosi (DFD-29) launchFDA approval Nov 4; launch expected late Q1/early Q2 2025 Launch underway; initial distribution ongoing; first prescriptions filled Launch initiated; first prescriptions filled; available via specialty pharmacy Progressing from approval to launch execution
UNLOXCYT (cosibelimab)PDUFA Dec 28, 2024; longer-term efficacy presented at ESMO FDA approval; Checkpoint deal with Sun Pharma announced Pending Sun Pharma acquisition; Fortress expects royalty and CVR optionality Transition from developer to royalty/monetization
CUTX-101 (Menkes)NDA rolling submission in Q4 2024 Priority Review; PDUFA Sept 30, 2025 Priority Review reiterated; PDUFA Sept 30, 2025 Advancing to approval decision
AI/Technology initiativesNot highlightedNot highlightedStrategic AI collaboration with Partex to source/evaluate assets New BD capability introduced
R&D execution (Triplex vaccine)Ongoing trials; transplant setting discussed Liver transplant trial funded; broader program detail First patient dosed in donor vaccination HSCT Phase 2 Program milestones continuing
Macro/tariffs/supply chainNot discussedNot discussedNot discussedNo material mention

Management Commentary

  • “Fortress entered 2025 with strong momentum… Checkpoint’s acquisition by Sun Pharma… expected ~$28 million at closing, future potential royalties, and a potential CVR payment.” — Lindsay A. Rosenwald, M.D. .
  • “Looking ahead, we are focused on key value drivers, including the… PDUFA action date for CUTX-101… Commercial launch of Emrosi is also underway with initial prescriptions filled at the end of March.” — Lindsay A. Rosenwald, M.D. .
  • On AI collaboration: “This collaboration with Partex will allow us to expeditiously identify and evaluate assets using their AI platform… We believe utilizing AI technology will allow us to scale more efficiently and cost effectively going forward.” — Lindsay A. Rosenwald, M.D. .

Q&A Highlights

  • No Q1 2025 earnings call transcript was available in our document corpus; no Q&A disclosures identified for this quarter .

Estimates Context

MetricQ1 2025 ActualQ1 2025 Consensus# of EstimatesSurprise
Revenue ($USD Millions)$13.139 $11.621*2*+$1.518M (Beat)*
Primary EPS ($USD)$(0.48) $(0.495)*2*+$0.015 (Beat)*

Note: Values marked with * are retrieved from S&P Global.

Key Takeaways for Investors

  • Emrosi’s launch provides the first organic commercial growth lever; monitor sequential prescription trends and SG&A discipline to assess margin trajectory .
  • Strategic monetization from Checkpoint’s sale (cash at closing, 2.5% UNLOXCYT royalty, CVR upside) can bolster liquidity and fund pipeline; closing timing (post May 28 vote) is a near-term catalyst .
  • CUTX-101’s PDUFA decision (Sept 30, 2025) with potential PRV ownership at Cyprium offers a tangible non-dilutive value event and could reshape medium-term capital allocation .
  • Operating expenses have improved YoY mainly on R&D moderation; sustaining opex control through commercialization ramp will be critical to narrowing losses and reducing financing dependence .
  • Thin analyst coverage implies potential estimate volatility; modest beats this quarter may support sentiment, but consistent execution and disclosure on launch metrics will matter more near term *.
  • Cash increased to $91.3M with notable contributions from subsidiaries (e.g., Checkpoint); tracking entity-level cash dynamics post-deal close will inform Fortress’s consolidated runway .
  • Watch for additional BD/AI-enabled in-licensing opportunities that fit Fortress’s royalty/dividend/asset-advancement model—supporting diversification and optionality .

Appendix: Additional Data Points

  • Journey Medical net product revenues: $13.1M in Q1 2025 vs $13.0M in Q1 2024 .
  • SG&A was $25.7M in Q1 2025 vs $17.9M in Q1 2024; R&D fell to $3.9M vs $24.8M YoY .
  • Cash breakdown (Q1 2025): Fortress+private $19.5M; Avenue $3.5M; Checkpoint $33.0M; Mustang $14.2M; Journey $21.1M .

Note: Values marked with * are retrieved from S&P Global.